CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II

CHEK2 mutations have been noted in bone, brain, breast, colon, lung, thyroid, and prostate cancer. Although now reported in both clear cell and non-clear cell renal cancer, we have not found CHEK2 2 mutations reported in the papillary type II subtype (PRCC). Here, we report a 63-year-old female with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez, Santiago J., Williams, H. James, Hogan, Thomas Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504490/
https://www.ncbi.nlm.nih.gov/pubmed/37719181
http://dx.doi.org/10.1016/j.eucr.2023.102421
Descripción
Sumario:CHEK2 mutations have been noted in bone, brain, breast, colon, lung, thyroid, and prostate cancer. Although now reported in both clear cell and non-clear cell renal cancer, we have not found CHEK2 2 mutations reported in the papillary type II subtype (PRCC). Here, we report a 63-year-old female with a PRCC type II with a concomitant CHEK2 C1100del mutation, who is currently in complete remission three years post tumor resection.

Ejemplares similares